Assure — Q1 2022 Earnings Presentation
15 slides from Assure's earnings presentation, May 16, 2022
Slide 1: First Quarter 2022 Results
First Quarter 2022 Results May 16, 2022 NASDAQ: IONM
Slide 2: Cautionary Note regarding Forward-Looking Statements
Cautionary Note regarding Forward - Looking Statements This presentation may contain “forward - looking statements” within the meaning of applicable securities laws. Forward - looking sta tements may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "shoul
Slide 3: Recent Developments
Assure Neuromonitoring | 3 Recent Developments • Record quarterly cash collections in 1Q’22 • Ramping higher margin remote neurology services platform • Contracted provider of IONM services for two additional Group Purchasing Organizations (GPOs) • Organic expansion into 13 th state • Key new hires
Slide 4: Revenue Cycle Management
Assure Neuromonitoring | 4 Revenue Cycle Management • The reserved accounts receivable in 1Q’22 was the result of an accounting charge made against aged receivables; not an accrual adjustment based on collections • Accounts receivable is automatically reserved at 24 months per Company policy; these
Slide 5: Cash Receipts
Assure Neuromonitoring | 5 Cash Receipts • Company is collecting a record 65% on receivables from the first 6 months after they were issued and 85% in first 12 months after they were issued for Assure’s 100% owned professional and technical entities $- $500,000 $1,000,000 $1,500,000 $2,000,000 $2,50
Slide 6: Remote Neurology Growth Objectives
Remote Neurology Growth Objectives * Based on current run rate 0 200 700 1,200 1,300 10,000 0 2,000 4,000 6,000 8,000 10,000 12,000 1Q'21 2Q'21 3Q'21 4Q'21 1Q'22 2022 Forecast* Number of Remote Neurology Managed Cases ** Assure Neuromonitoring | 6 ** See Safe Harbor for definition of Remote Neurolog
Slide 7: Deep Pipeline of Expansion Opportunities
Deep Pipeline of Expansion Opportunities Existing Operational Footprint and Targeted States • Expanded into one new state thus far in 2022 • Adding density in existing markets • Numerous M&A opportunities • Extending medical device distributor network that has already facilitated expansion into new
Slide 8: Teaming with Group Purchasing Organizations (GPOs)
Teaming with Group Purchasing Organizations (GPOs) Assure Neuromonitoring | 8 • Assure’s selection as supplier of IONM services for these GPOs was based on superior clinical care, quality of service, competitive pricing, as well as recognition that the Company has capacity to scale and support cover
Slide 9: Adding Talent to Leadership Team
Adding Talent to Leadership Team Assure Neuromonitoring | 9 • Assure has onboarded leaders with skill sets the Company did not have before to support and drive it on the next leg of our growth journey Brian McDonald VP, Business Operations Kelly Shelton VP, Sales Sherri Wagner VP, Human Resources Ja
Slide 10: Drivers and Trends in Managed Cases
Assure Neuromonitoring | 10 Drivers and Trends in Managed Cases 1,600 3,000 6,400 9,900 17,400 25,000 0 3,000 6,000 9,000 12,000 15,000 18,000 21,000 24,000 27,000 Number of Managed Cases * + * See Safe Harbor for definition of Managed Cases All operations in Colorado Operational footprint expands t
Slide 11: 1Q'22 Financial Highlights
1Q’22 Financial Highlights 5,100 2,800 0 1,000 2,000 3,000 4,000 5,000 6,000 1Q'22 1Q'21 Managed Cases * $4.7 $4.8 $0 $2 $4 $6 1Q'22 1Q'21 Revenue ($1.7) ($1.0) ($2.0) ($1.5) ($1.0) ($0.5) $0.0 1Q'22 1Q'21 Adj. EBITDA ** ($m) ($m) Assure Neuromonitoring | 11 ** See reconciliations of non - GAAP resu
Slide 12: Balance Sheet and Cash Flow Supports Growth Objectives
Balance Sheet and Cash Flow Supports Growth Objectives Capitalization • Strengthened financial position: – $5.2m institutional investor - led private placement + mgmt. and board participation (Nov ‘21) – $11m credit facility secured with Centurion (Jun ‘21) – $10.5m private placement with Special Si
Slide 13: Q&A
Q&A Assure Holdings 7887 E. Belleview Ave., Suite 500, Englewood, CO (720) 617 - 2526 www.assureneuromonitoring.com Company Contact John Farlinger Executive Chairman and CEO John.Farlinger@assureiom.com Investor Relations Scott Kozak Director, Investor and Media Relations Scott.Kozak@assureiom.com A
Slide 14: 1Q'22 Earnings Call - Appendix
1Q’22 Earnings Call - Appendix May 16, 2022 NASDAQ: IONM
Slide 15: Non-GAAP Financial Measures Reconciliation
Non - GAAP Financial Measures Reconciliation Assure Neuromonitoring | 15 2022 EBITDA Net Income (loss) (2,459) $ (1,231) $ Interest expense 407 18 Accretion expense 170 95 Income tax (337) (427) Depreciation and amortization 258 285 EBITDA (1,961) (1,260) Stock-based compensation 323 279 Provision f